Deferred registration - Klear Bio Code: KLR003-Clin-004
| ISRCTN | ISRCTN16425757 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN16425757 |
| Clinical Trials Information System (CTIS) | 2026-525575-22-00 |
| Integrated Research Application System (IRAS) | 1014010 |
| Central Portfolio Management System (CPMS) | 76628 |
| Sponsor code | KLR003-Clin-004 |
| Sponsor | Klear Bio, Inc. |
| Funder | Klear Bio, Inc. |
- Submission date
- 24/09/2026
- Registration date
- 01/10/2026
- Last edited
- 06/11/2026
- Recruitment status
- Recruiting
- Overall study status
- Deferred
- Condition category
- Other
Plain English summary of protocol
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Contact information
Public
Klear Bio, Inc.
300 Technology Square, 8th Floor
Cambridge
MA 02139
United States of America
| Phone | +1 (617) 256-2763 |
|---|---|
| clinicaltrials@klear.bio |
Scientific
Klear Bio, Inc.
300 Technology Square, 8th Floor
Cambridge
MA 02139
United States of America
| Phone | +1 (617) 256-2763 |
|---|---|
| Tim@klear.bio |
Principal investigator
Medicines Evaluation Unit (MEU) Ltd
The Langley Building
Southmoor Road
Manchester
M23 9QZ6
United Kingdom
| Phone | +44 0161 946 4071 |
|---|---|
| hhunter@meu.org.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Purpose | Treatment |
| Scientific title | Deferred registration - Klear Bio Code: KLR003-Clin-004 [Full scientific title to be added on or before the deferral expiry date] |
| Study objectives | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Ethics approval(s) |
Approved 10/09/2026, North East - York Research Ethics Committee (Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; york.rec@hra.nhs.uk), ref: 26/NE/0079 |
| Health condition(s) or problem(s) studied | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Intervention | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 30/10/2028 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 65 Years |
| Sex | All |
| Target sample size at registration | 183 |
| Key inclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Key exclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Date of first enrolment | 13/05/2026 |
| Date of final enrolment | 05/06/2028 |
Locations
Countries of recruitment
- United Kingdom
- England
- Netherlands
- United States of America
Study participating centre
-
-
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
06/11/2026: Internal review.
25/09/2026: Study's existence confirmed by the Health Research Authority (HRA) (UK).